Global Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Comprehensive Study by Disease Type (Emphysema, Chronic Bronchitis), Age Group (Children, Adults), Treatment Type (Medication, Oxygen Therapy, Pulmonary Rehabilitation, Surgery), End User (Hospital & Clinics, Rehabilitation Centers, Home Care Settings, Others) Players and Region - Global Market Outlook to 2030

Chronic Obstructive Pulmonary Disease Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Chronic Obstructive Pulmonary Disease Market Overview:
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects everyday life and difficult to get outside. Its symptom includes chronic cough, sputum production, and dyspnea which worsen over time. The increase in COPD globally is attributed to changes in lifestyles, smoking habits and levels of air pollution together with the ageing population. Growing market demand for solutions that reduce hospitalizations, improve quality of life and enable effective remote patient monitoring is expected to drive the market significantly. Further, development and delivery of new treatments, including new bronchodilators, anti-inflammatory drugs and innovative gene therapies, offer potential advances in the treatment of COPD which is expected to fuel the growth. Technological advancements such as telehealth platforms, AI-powered diagnostic tools and digital therapies are revolutionizing COPD market by improving diagnostic accuracy, facilitating continuous monitoring and improving patient education.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Development of New Therapies Such as Long-Acting Bronchodilators and Phosphodiesterase-4 (PDE4) Inhibitors

Market Growth Drivers:
Rising Prevalence of COPD Due to Changing Lifestyle and Exposure to Air Pollution and Growing Demand for Homecare Solutions Such as Home Oxygen Therapy, Nebulizers, Etc.

Challenges:
Lack of Awareness Among People and Limited Availability of Treatment options in Rural Areas

Restraints:
Strict Regulations for Approval of COPD Medicines or Therapies

Opportunities:
Development of Cost-Effective Medications And Other Therapies to Address COPD Treatment for Developing Countries

Competitive Landscape:
The key players are targeting the innovations of the Solutions with better quality, better technical characteristics. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking upon mergers and acquisitions in order to maintain their presence in the market.
Some of the key players profiled in the report are GSK plc (United Kingdom), AstraZeneca (United Kingdom), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Boehringer Ingelheim (Germany), Lupin Limited (India), Astellas Pharma (Japan), Abbott Laboratories (United States), Almirall, S.A. (Spain) and Merck & Co., Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Chronic Obstructive Pulmonary Disease market by 2030. Considering Market by Disease Type, the sub-segment i.e. Emphysema will boost the Chronic Obstructive Pulmonary Disease market. Considering Market by Age Group, the sub-segment i.e. Children will boost the Chronic Obstructive Pulmonary Disease market. Considering Market by Treatment Type, the sub-segment i.e. Medication will boost the Chronic Obstructive Pulmonary Disease market. Considering Market by End User, the sub-segment i.e. Hospital & Clinics will boost the Chronic Obstructive Pulmonary Disease market.

What Can be Explored with the Chronic Obstructive Pulmonary Disease Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Chronic Obstructive Pulmonary Disease Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Chronic Obstructive Pulmonary Disease
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Chronic Obstructive Pulmonary Disease market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Chronic Obstructive Pulmonary Disease market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Chronic Obstructive Pulmonary Disease (COPD) Drug & treatment Providers, Healthcare Companies, Government Bodies, Research Organizations, End User Industries and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Disease Type
  • Emphysema
  • Chronic Bronchitis

By Age Group
  • Children
  • Adults

By Treatment Type
  • Medication
  • Oxygen Therapy
  • Pulmonary Rehabilitation
  • Surgery

By End User
  • Hospital & Clinics
  • Rehabilitation Centers
  • Home Care Settings
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of COPD Due to Changing Lifestyle and Exposure to Air Pollution
      • 3.2.2. Growing Demand for Homecare Solutions Such as Home Oxygen Therapy, Nebulizers, Etc.
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness Among People and Limited Availability of Treatment options in Rural Areas
    • 3.4. Market Trends
      • 3.4.1. Development of New Therapies Such as Long-Acting Bronchodilators and Phosphodiesterase-4 (PDE4) Inhibitors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chronic Obstructive Pulmonary Disease, by Disease Type, Age Group, Treatment Type, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Chronic Obstructive Pulmonary Disease (Value)
      • 5.2.1. Global Chronic Obstructive Pulmonary Disease by: Disease Type (Value)
        • 5.2.1.1. Emphysema
        • 5.2.1.2. Chronic Bronchitis
      • 5.2.2. Global Chronic Obstructive Pulmonary Disease by: Age Group (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
      • 5.2.3. Global Chronic Obstructive Pulmonary Disease by: Treatment Type (Value)
        • 5.2.3.1. Medication
        • 5.2.3.2. Oxygen Therapy
        • 5.2.3.3. Pulmonary Rehabilitation
        • 5.2.3.4. Surgery
      • 5.2.4. Global Chronic Obstructive Pulmonary Disease by: End User (Value)
        • 5.2.4.1. Hospital & Clinics
        • 5.2.4.2. Rehabilitation Centers
        • 5.2.4.3. Home Care Settings
        • 5.2.4.4. Others
      • 5.2.5. Global Chronic Obstructive Pulmonary Disease Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Chronic Obstructive Pulmonary Disease (Price)
  • 6. Chronic Obstructive Pulmonary Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GSK plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boehringer Ingelheim (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lupin Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Astellas Pharma (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Almirall, S.A. (Spain)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck & Co., Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Chronic Obstructive Pulmonary Disease Sale, by Disease Type, Age Group, Treatment Type, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Chronic Obstructive Pulmonary Disease (Value)
      • 7.2.1. Global Chronic Obstructive Pulmonary Disease by: Disease Type (Value)
        • 7.2.1.1. Emphysema
        • 7.2.1.2. Chronic Bronchitis
      • 7.2.2. Global Chronic Obstructive Pulmonary Disease by: Age Group (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
      • 7.2.3. Global Chronic Obstructive Pulmonary Disease by: Treatment Type (Value)
        • 7.2.3.1. Medication
        • 7.2.3.2. Oxygen Therapy
        • 7.2.3.3. Pulmonary Rehabilitation
        • 7.2.3.4. Surgery
      • 7.2.4. Global Chronic Obstructive Pulmonary Disease by: End User (Value)
        • 7.2.4.1. Hospital & Clinics
        • 7.2.4.2. Rehabilitation Centers
        • 7.2.4.3. Home Care Settings
        • 7.2.4.4. Others
      • 7.2.5. Global Chronic Obstructive Pulmonary Disease Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Chronic Obstructive Pulmonary Disease (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chronic Obstructive Pulmonary Disease: by Disease Type(USD Million)
  • Table 2. Chronic Obstructive Pulmonary Disease Emphysema , by Region USD Million (2018-2023)
  • Table 3. Chronic Obstructive Pulmonary Disease Chronic Bronchitis , by Region USD Million (2018-2023)
  • Table 4. Chronic Obstructive Pulmonary Disease: by Age Group(USD Million)
  • Table 5. Chronic Obstructive Pulmonary Disease Children , by Region USD Million (2018-2023)
  • Table 6. Chronic Obstructive Pulmonary Disease Adults , by Region USD Million (2018-2023)
  • Table 7. Chronic Obstructive Pulmonary Disease: by Treatment Type(USD Million)
  • Table 8. Chronic Obstructive Pulmonary Disease Medication , by Region USD Million (2018-2023)
  • Table 9. Chronic Obstructive Pulmonary Disease Oxygen Therapy , by Region USD Million (2018-2023)
  • Table 10. Chronic Obstructive Pulmonary Disease Pulmonary Rehabilitation , by Region USD Million (2018-2023)
  • Table 11. Chronic Obstructive Pulmonary Disease Surgery , by Region USD Million (2018-2023)
  • Table 12. Chronic Obstructive Pulmonary Disease: by End User(USD Million)
  • Table 13. Chronic Obstructive Pulmonary Disease Hospital & Clinics , by Region USD Million (2018-2023)
  • Table 14. Chronic Obstructive Pulmonary Disease Rehabilitation Centers , by Region USD Million (2018-2023)
  • Table 15. Chronic Obstructive Pulmonary Disease Home Care Settings , by Region USD Million (2018-2023)
  • Table 16. Chronic Obstructive Pulmonary Disease Others , by Region USD Million (2018-2023)
  • Table 17. South America Chronic Obstructive Pulmonary Disease, by Country USD Million (2018-2023)
  • Table 18. South America Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 19. South America Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 20. South America Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 21. South America Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 22. Brazil Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 23. Brazil Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 24. Brazil Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 25. Brazil Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 26. Argentina Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 27. Argentina Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 28. Argentina Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 29. Argentina Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 30. Rest of South America Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 31. Rest of South America Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 32. Rest of South America Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 33. Rest of South America Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 34. Asia Pacific Chronic Obstructive Pulmonary Disease, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 36. Asia Pacific Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 37. Asia Pacific Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 38. Asia Pacific Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 39. China Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 40. China Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 41. China Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 42. China Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 43. Japan Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 44. Japan Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 45. Japan Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 46. Japan Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 47. India Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 48. India Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 49. India Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 50. India Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 51. South Korea Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 52. South Korea Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 53. South Korea Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 54. South Korea Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 55. Taiwan Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 56. Taiwan Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 57. Taiwan Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 58. Taiwan Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 59. Australia Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 60. Australia Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 61. Australia Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 62. Australia Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 67. Europe Chronic Obstructive Pulmonary Disease, by Country USD Million (2018-2023)
  • Table 68. Europe Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 69. Europe Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 70. Europe Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 71. Europe Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 72. Germany Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 73. Germany Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 74. Germany Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 75. Germany Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 76. France Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 77. France Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 78. France Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 79. France Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 80. Italy Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 81. Italy Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 82. Italy Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 83. Italy Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 84. United Kingdom Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 85. United Kingdom Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 86. United Kingdom Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 87. United Kingdom Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 88. Netherlands Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 89. Netherlands Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 90. Netherlands Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 91. Netherlands Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 92. Rest of Europe Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 93. Rest of Europe Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 94. Rest of Europe Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 95. Rest of Europe Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 96. MEA Chronic Obstructive Pulmonary Disease, by Country USD Million (2018-2023)
  • Table 97. MEA Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 98. MEA Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 99. MEA Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 100. MEA Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 101. Middle East Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 102. Middle East Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 103. Middle East Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 104. Middle East Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 105. Africa Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 106. Africa Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 107. Africa Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 108. Africa Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 109. North America Chronic Obstructive Pulmonary Disease, by Country USD Million (2018-2023)
  • Table 110. North America Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 111. North America Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 112. North America Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 113. North America Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 114. United States Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 115. United States Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 116. United States Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 117. United States Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 118. Canada Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 119. Canada Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 120. Canada Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 121. Canada Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 122. Mexico Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2018-2023)
  • Table 123. Mexico Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2018-2023)
  • Table 124. Mexico Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2018-2023)
  • Table 125. Mexico Chronic Obstructive Pulmonary Disease, by End User USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Chronic Obstructive Pulmonary Disease: by Disease Type(USD Million)
  • Table 138. Chronic Obstructive Pulmonary Disease Emphysema , by Region USD Million (2025-2030)
  • Table 139. Chronic Obstructive Pulmonary Disease Chronic Bronchitis , by Region USD Million (2025-2030)
  • Table 140. Chronic Obstructive Pulmonary Disease: by Age Group(USD Million)
  • Table 141. Chronic Obstructive Pulmonary Disease Children , by Region USD Million (2025-2030)
  • Table 142. Chronic Obstructive Pulmonary Disease Adults , by Region USD Million (2025-2030)
  • Table 143. Chronic Obstructive Pulmonary Disease: by Treatment Type(USD Million)
  • Table 144. Chronic Obstructive Pulmonary Disease Medication , by Region USD Million (2025-2030)
  • Table 145. Chronic Obstructive Pulmonary Disease Oxygen Therapy , by Region USD Million (2025-2030)
  • Table 146. Chronic Obstructive Pulmonary Disease Pulmonary Rehabilitation , by Region USD Million (2025-2030)
  • Table 147. Chronic Obstructive Pulmonary Disease Surgery , by Region USD Million (2025-2030)
  • Table 148. Chronic Obstructive Pulmonary Disease: by End User(USD Million)
  • Table 149. Chronic Obstructive Pulmonary Disease Hospital & Clinics , by Region USD Million (2025-2030)
  • Table 150. Chronic Obstructive Pulmonary Disease Rehabilitation Centers , by Region USD Million (2025-2030)
  • Table 151. Chronic Obstructive Pulmonary Disease Home Care Settings , by Region USD Million (2025-2030)
  • Table 152. Chronic Obstructive Pulmonary Disease Others , by Region USD Million (2025-2030)
  • Table 153. South America Chronic Obstructive Pulmonary Disease, by Country USD Million (2025-2030)
  • Table 154. South America Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 155. South America Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 156. South America Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 157. South America Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 158. Brazil Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 159. Brazil Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 160. Brazil Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 161. Brazil Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 162. Argentina Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 163. Argentina Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 164. Argentina Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 165. Argentina Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 166. Rest of South America Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 167. Rest of South America Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 168. Rest of South America Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 169. Rest of South America Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 170. Asia Pacific Chronic Obstructive Pulmonary Disease, by Country USD Million (2025-2030)
  • Table 171. Asia Pacific Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 172. Asia Pacific Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 173. Asia Pacific Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 174. Asia Pacific Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 175. China Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 176. China Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 177. China Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 178. China Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 179. Japan Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 180. Japan Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 181. Japan Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 182. Japan Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 183. India Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 184. India Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 185. India Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 186. India Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 187. South Korea Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 188. South Korea Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 189. South Korea Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 190. South Korea Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 191. Taiwan Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 192. Taiwan Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 193. Taiwan Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 194. Taiwan Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 195. Australia Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 196. Australia Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 197. Australia Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 198. Australia Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 203. Europe Chronic Obstructive Pulmonary Disease, by Country USD Million (2025-2030)
  • Table 204. Europe Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 205. Europe Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 206. Europe Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 207. Europe Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 208. Germany Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 209. Germany Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 210. Germany Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 211. Germany Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 212. France Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 213. France Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 214. France Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 215. France Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 216. Italy Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 217. Italy Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 218. Italy Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 219. Italy Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 220. United Kingdom Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 221. United Kingdom Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 222. United Kingdom Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 223. United Kingdom Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 224. Netherlands Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 225. Netherlands Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 226. Netherlands Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 227. Netherlands Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 228. Rest of Europe Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 229. Rest of Europe Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 230. Rest of Europe Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 231. Rest of Europe Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 232. MEA Chronic Obstructive Pulmonary Disease, by Country USD Million (2025-2030)
  • Table 233. MEA Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 234. MEA Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 235. MEA Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 236. MEA Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 237. Middle East Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 238. Middle East Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 239. Middle East Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 240. Middle East Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 241. Africa Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 242. Africa Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 243. Africa Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 244. Africa Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 245. North America Chronic Obstructive Pulmonary Disease, by Country USD Million (2025-2030)
  • Table 246. North America Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 247. North America Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 248. North America Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 249. North America Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 250. United States Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 251. United States Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 252. United States Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 253. United States Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 254. Canada Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 255. Canada Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 256. Canada Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 257. Canada Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 258. Mexico Chronic Obstructive Pulmonary Disease, by Disease Type USD Million (2025-2030)
  • Table 259. Mexico Chronic Obstructive Pulmonary Disease, by Age Group USD Million (2025-2030)
  • Table 260. Mexico Chronic Obstructive Pulmonary Disease, by Treatment Type USD Million (2025-2030)
  • Table 261. Mexico Chronic Obstructive Pulmonary Disease, by End User USD Million (2025-2030)
  • Table 262. Research Programs/Design for This Report
  • Table 263. Key Data Information from Secondary Sources
  • Table 264. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chronic Obstructive Pulmonary Disease: by Disease Type USD Million (2018-2023)
  • Figure 5. Global Chronic Obstructive Pulmonary Disease: by Age Group USD Million (2018-2023)
  • Figure 6. Global Chronic Obstructive Pulmonary Disease: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Chronic Obstructive Pulmonary Disease: by End User USD Million (2018-2023)
  • Figure 8. South America Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 9. Asia Pacific Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 10. Europe Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 11. MEA Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 12. North America Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 13. Global Chronic Obstructive Pulmonary Disease share by Players 2023 (%)
  • Figure 14. Global Chronic Obstructive Pulmonary Disease share by Players (Top 3) 2023(%)
  • Figure 15. Global Chronic Obstructive Pulmonary Disease share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GSK plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GSK plc (United Kingdom) Revenue: by Geography 2023
  • Figure 19. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 25. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 29. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 30. Lupin Limited (India) Revenue: by Geography 2023
  • Figure 31. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Astellas Pharma (Japan) Revenue: by Geography 2023
  • Figure 33. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 34. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 35. Almirall, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 36. Almirall, S.A. (Spain) Revenue: by Geography 2023
  • Figure 37. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Global Chronic Obstructive Pulmonary Disease: by Disease Type USD Million (2025-2030)
  • Figure 40. Global Chronic Obstructive Pulmonary Disease: by Age Group USD Million (2025-2030)
  • Figure 41. Global Chronic Obstructive Pulmonary Disease: by Treatment Type USD Million (2025-2030)
  • Figure 42. Global Chronic Obstructive Pulmonary Disease: by End User USD Million (2025-2030)
  • Figure 43. South America Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 44. Asia Pacific Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 45. Europe Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 46. MEA Chronic Obstructive Pulmonary Disease Share (%), by Country
  • Figure 47. North America Chronic Obstructive Pulmonary Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GSK plc (United Kingdom)
  • AstraZeneca (United Kingdom)
  • Pfizer Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Novartis AG (Switzerland)
  • Boehringer Ingelheim (Germany)
  • Lupin Limited (India)
  • Astellas Pharma (Japan)
  • Abbott Laboratories (United States)
  • Almirall, S.A. (Spain)
  • Merck & Co., Inc. (United States)
Select User Access Type

Key Highlights of Report


Jul 2024 208 Pages 51 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chronic Obstructive Pulmonary Disease Quantitative research analysis
Global Chronic Obstructive Pulmonary Disease Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Chronic Obstructive Pulmonary Disease market are GSK plc (United Kingdom), AstraZeneca (United Kingdom), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Boehringer Ingelheim (Germany), Lupin Limited (India), Astellas Pharma (Japan), Abbott Laboratories (United States), Almirall, S.A. (Spain) and Merck & Co., Inc. (United States), to name a few.
"Development of New Therapies Such as Long-Acting Bronchodilators and Phosphodiesterase-4 (PDE4) Inhibitors" is seen as one of major influencing trends for Chronic Obstructive Pulmonary Disease Market during projected period 2023-2030.

Know More About Global Chronic Obstructive Pulmonary Disease Report?

Have a Query? Click Here

Other Related Reports

T-Cell Immunotherapy Comprehensive Study by Type (Active Immunotherapy, Passive Immunotherapy), Application (Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophagus Cancer, Pancreatic Cancer, Other...
$ 3750
Malaria Diagnostics Comprehensive Study by Type (Microscopy, Rapid Diagnostic Tests, Molecular Diagnostic Tests (Conventional PCR, Real-Time PCR (quantitative PCR or qPCR))), End User (Clinics, Hospi...
$ 3350
Minimally Invasive Surgery Comprehensive Study by Type (Endoscopic Devices, Electrosurgical Devices, Monitoring and Visualization Devices), Application (Cosmetic Surgery, Cardiac Surgery, Gastrointes...
$ 3650
Therapeutic Drug Monitoring Comprehensive Study by Type (Consumable, Equipment (Immunoassay analyzer)), Application (Hospitals (Clinical Pharmacology departments), Pathological labs, Research and Aca...
$ 3750
Digital Therapeutics Comprehensive Study by Disease (Diabetes, Obesity, Cardiovascular Diseases (CVD), Central Nervous System (CNS) Disease, Gastrointestinal Disorders (GID), Respiratory Diseases, Sm...
$ 3650
Kidney Fibrosis Treatment Comprehensive Study by Therapeutics (Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase In...
$ 3350